The Efficacy of Nitric Oxide in Stroke (ENOS) Trial
Information source: University of Nottingham
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Stroke
Intervention: Transdermal glyceryl trinitrate patch (Drug); Pre-stroke antihypertensives (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: University of Nottingham Official(s) and/or principal investigator(s): Philip Bath, Principal Investigator, Affiliation: University of Nottingham
Overall contact: Philip Bath, Email: philip.bath@nottingham.ac.uk
Summary
Nitric oxide is a multimodal candidate treatment for acute stroke having a number of
properties which may be beneficial in acute stroke, including lowering blood pressure,
causing cerebral vasodilation, and improving central and systemic haemodynamics. Nitric
oxide donors are effective in experimental stroke and pilot studies in patients suggest that
one, glyceryl trinitrate, can be delivered easily in a transdermal preparation. Around half
of all patients admitted with acute stroke are taking antihypertensive therapy immediately
prior to their stroke. No data exist as to whether it is beneficial or safe to stop or
continue this treatment during the acute phase. ENOS is a prospective, international,
multicentre, randomised, parallel-group, blinded, controlled, collaborative, factorial trial
designed to test two questions related to the management of blood pressure immediately
post-stroke:
1. The safety and efficacy of nitric oxide, given as transdermal glyceryl trinitrate.
2. The safety and efficacy of stopping or continuing prior antihypertensive medication.
Previously independent adult patients who are conscious and have residual limb weakness are
eligible for enrollment. Central randomisation will be performed via the internet. Treatment
is initiated within 48 hours of stroke onset and is given as daily glyceryl trinitrate
patches for 7 days. A computed tomography (CT) scan is required within 7 days of
randomisation. Early follow-up is performed locally over the 7 days of treatment, including
blood pressure, early stroke events, and adverse events. Telephone central follow-up by the
trial co-ordinating centre will be performed at 3 months. The primary outcome is combined
death or dependency (modified Rankin Score >2).
Clinical Details
Official title: A Prospective, Collaborative, International, Multicentre, Randomised, Parallel-group, Single and Outcome Blinded, Controlled, Factorial Trial to Investigate the Safety and Efficacy of Treatment With Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, and of Continuing or Stopping Temporarily Pre-stroke Antihypertensive Therapy, in Patients With Acute Stroke
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Reduced death or dependency (modified Rankin score)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult(> 18 yrs).
- Clinical stroke syndrome with limb weakness lasting at least 1 hour i. e. not likely
to be a transient ischaemic attack).
- Limb weakness (SNSS Arm <6 and/or Leg <6).
- Onset < 48 hours.
- Conscious (Glasgow Coma Scale > 8).
- Independent prior to stroke (pre-morbid Rankin scale < 2).
- Meaningful consent, or assent from a relative or carer
Exclusion Criteria:
- Definite need for nitrate therapy
- Contraindication to nitrate therapy
- Definite need for prior antihypertensive or anti-anginal medication
- Definite need for antihypertensive therapy during acute stroke
- Systolic blood pressure <140 mmHg or >220 mmHg.
- Patients expected to require surgical intervention
- Known intracerebral pathology other than stroke
- Other serious condition which is likely to prevent outcome assessment at 3 months
- Previous enrollment in ENOS or current involvement in another trial of an
experimental drug intervention.
- Not available for follow-up -Females of childbearing potential, pregnancy or
breastfeeding. -
Locations and Contacts
Philip Bath, Email: philip.bath@nottingham.ac.uk
Nottingham University Hospitals NHS Trust (City Hospital), Nottingham, Nottinghamshire NG5 1PJ, United Kingdom; Recruiting
Additional Information
Starting date: July 2001
Last updated: July 23, 2012
|